4.8 Article

Amyotrophic lateral sclerosis

Journal

LANCET
Volume 377, Issue 9769, Pages 942-955

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(10)61156-7

Keywords

-

Funding

  1. Sanofi-Aventis
  2. Serono Pharmaceuticals
  3. Merck Sorono
  4. National Health and Medical Research Council of Australia [510233, 568743]
  5. Motor Neurone Disease Research Institute
  6. Irish Health Research Board
  7. American ALS Association
  8. Irish Motor Neurone Disease Research Foundation
  9. Medical Research Council
  10. Clive and Vera Ramacciotti grant
  11. Charles Viertel grant
  12. Merck Serono Australia
  13. Novartis Australia
  14. Medical Research Council [G0701923] Funding Source: researchfish
  15. MRC [G0701923] Funding Source: UKRI

Ask authors/readers for more resources

Amyotrophic lateral sclerosis (ALS) is an idiopathic, fatal neurodegenerative disease of the human motor system. In this Seminar, we summarise current concepts about the origin of the disease, what predisposes patients to develop the disorder, and discuss why all cases of ALS are not the same. In the 150 years since Charcot originally described ALS, painfully slow progress has been made towards answering these questions. We focus on what is known about ALS and where research is heading-from the small steps of extending longevity, improving therapies, undertaking clinical trials, and compiling population registries to the overarching goals of establishing the measures that guard against onset and finding the triggers for this neurodegenerative disorder.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available